Opioids are widely used in chronic non-cancer pain (CNCP) management. However, they remain controversial due to serious risk of causing opioid use disorder (OUD). Our main aim was develop a predictive model for future clinical translation that include pharmacogenetic markers.

Analgesic-response variability in chronic noncancer pain (CNCP) has been reported due to several biological and environmental factors. This study was undertaken explore sex differences linked OPRM1 COMT DNA methylation changes genetic variants analgesic response. A retrospective with 250 real-world CNCP outpatients performed which data from demographic, clinical, pharmacological variables were collected. levels (CpG island) evaluated by pyrosequencing, their interaction the (A118G) (G472A)...

Introduction: Opioid deprescription is the process of supervised tapering and safe withdrawal when a potentially inappropriate use detected. This represents challenge in chronic non-cancer pain (CNCP) patients who may respond differently to procedure. Our aim was analyze potential impact CYP2D6 phenotypes sex on clinical safety outcomes during an opioid disorder (OUD) process. Methods: A prospective observational study conducted CNCP ambulatory OUD (cases, n = 138) underwent 6-month dose...

Interindividual variability in analgesic response is at least partly due to well-characterized polymorphisms that are associated with opioid dosing and adverse outcomes. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has put forward recommendations for the CYP2D6 phenotype, but list of studied drug-gene pairs continues grow. This clinical trial randomized chronic pain patients (n = 60), referred from primary care unit into two prescribing arms, one guided by CYP2D6, μ-opioid...

The threats involved in the long-term opioid treatment of chronic non-cancer pain (CNCP) have increased notably. Strategies to identify at-risk patients are important because there is no clear evidence showing which screening or deprescription programmes appropriate. Our aim was evaluate provided by pharmacogenetics applied predict an analgesic toxicity profile prescription use disorder (POUD) participating programme. Pharmacogenetic markers were analysed observational, prospective programme...

Several opioids have pharmacogenetic and drug-drug interactions which may compromise their analgesic effectiveness, but are not routinely implemented into supportive pain management. We hypothesized that CYP2D6 phenotypes concomitant use of substrates or inhibitors would correlate with opioid outcomes.

Intellectual disability (ID) and autism spectrum disorder (ASD) are common, co-occurring developmental disorders frequently associated with sleep problems. This study aimed to assess the effectiveness tolerability of agomelatine as a pharmacotherapy for problems in ASD adults ID.A randomised, crossover, triple-blind, placebo-controlled clinical trial, two three-month periods treatment starting either or placebo washout period weeks. Ambulatory circadian monitoring (24 hours/7 days) evaluated...

Abstract Screening for opioid use disorder should be considered in chronic non‐cancer pain (CNCP) patients with long‐term of opioids. The aim our study was to assess the effectiveness an individualized treatment plan (ITP) prescription dependence that included screening pharmacogenetic markers. An observational prospective performed using opioid‐dependent CNCP outpatients ( n = 88). Patients were divided into nonresponders, responders, or high responders according their response ITP....

Abstract Tapentadol (TAP) and oxycodone/naloxone (OXN) potentially offer an improved opioid tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. Our aim was to compare effectiveness security daily practice, together with the influence of pharmacogenetic markers. An observational study developed ambulatory test cases under TAP (n = 194) or OXN 175) prescription controls (prescribed other opioids (control), n 216) CNCP patients. Pain intensity relief,...

Objective: To quantify patients' pain more objectively is essential to guide an individualized therapy, all the so in patients under long-term opioid-use. Only a thoughtful and objective understanding of risks benefits could improve standard care. Our aim was assess metric reliability validity integrated self-report Global Pain Status questionnaire impact on patient's health precise manner.

Abstract Opioid use disorder (OUD) is a multifaceted condition influenced by sex, genetic and environmental factors that could be linked with epigenetic changes. Understanding how these interact crucial to understand address the development progression of this disorder. Our aim was elucidate different potential mechanisms between women men correlate OUD under real‐world pain unit conditions. Associations analgesic response DNA methylation level opioid mu receptor ( OPRM1 ) gene (CpG sites...

Abstract Objectives Chronic pain is one of the most common reasons individuals seek medical attention. It a major issue because wide interindividual variability in analgesic response. This might be partly explained by presence variants genes encoding molecules involved pharmacodynamics and pharmacokinetics. The aim was to analyze opioid effectiveness chronic low back ( CLBP ) relief after titration, unveiling impact pharmacogenetics. Methods study included 231 opioid‐naïve patients from...

Background Safety data from long‐term opioid therapy in the real world has been poorly studied chronic non‐cancer pain ( CNCP ). The aim was to design a pharmacovigilance recording system and assess whether participation this improves management, enhancing patient′s health status. Methods A conducted during 24 months. Data were self‐reported by patients (pain, adverse events [ AE s] healthcare resources use) physicians (morphine equivalent daily dose MEDD ] prescribed suspected drug reaction...

Despite the large body of research on sex differences in pain, there is a lack translation to real-world pain management. Our aim was analyse analgesic response oxycodone/naloxone (OXN) and tapentadol (TAP), comparison with other opioids (OPO) commonly prescribed for chronic non-cancer (CNCP). An observational cross-sectional study conducted ambulatory CNCP patients (n = 571). Sociodemographic, clinical (pain intensity, relief, quality life), safety (adverse events (AEs), adverse drug...

(1) Background: It is essential to focus attention on sex-specific factors which are clinically relevant in pain management, especially with regards opioid use disorder (OUD) risk. The aim of this study was explore potential sex-differences chronic non-cancer (CNCP) outpatients. (2) Methods: An observational cross-sectional conducted under CNCP outpatients long-term prescribed opioids (n = 806), wherein 137 patients had an OUD diagnosis (cases, 64% females) and 669 did not (controls, 66%...

More than half of patients with opioid use disorder for chronic non-cancer pain (CNCP) reduced their dose through a progressive withdrawal supported by rotation to buprenorphine and/or tramadol. The aim this research is analyse the long-term effectiveness deprescription taking into account impact sex and pharmacogenetics on inter-individual variability. A cross-sectional study was carried out from October 2019 June 2020 CNCP who had previously undergone an (n = 119 patients). Demographic,...

Objectives: The use of opioids to relieve pain is a challenge because the high variability in dose requirements and tolerance profiles. Among potential modulators are individual’s genetic background being female. Our aim was evaluate sex bias genotype-related influence on opioid titration safety, chronic low back (CLBP), most frequent noncancer pain. Methods: A 3-year prospective study developed opioid-naive CLBP patients. Data were self-reported by patients (pain [Visual Analogy Scale],...